Comparative Pharmacology
Head-to-head clinical analysis: EDURANT versus INTELENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDURANT versus INTELENCE.
EDURANT vs INTELENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase, causing conformational changes that inhibit enzyme activity and viral replication.
Non-nucleoside reverse transcriptase inhibitor (NNRTI). Binds directly to HIV-1 reverse transcriptase, causing allosteric inhibition of RNA-dependent and DNA-dependent DNA polymerase activities.
25 mg orally once daily with a meal.
200 mg orally twice daily after a meal.
None Documented
None Documented
Terminal half-life 38 hours (range 25-57 h); supports once-daily dosing, steady state at ~7 days
Terminal elimination half-life is approximately 40 hours (range 30-60 hours). This supports once-daily dosing with 400 mg (two 200 mg tablets) after initial twice-daily dosing for 2 weeks, but note that etravirine is only approved for twice-daily dosing (200 mg twice daily) in treatment-experienced patients.
Renal (~25% unchanged) and fecal (~60% as metabolites); total recovery ~85%
Primarily fecal (76.6% as unchanged drug or metabolites) with minor renal excretion (19.6%, of which 1.2% is unchanged). Biliary elimination of metabolites may occur.
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral